Abstract
We previously developed a robust prognostic model (GS model) to predict the survival outcome of patients with advanced pancreatic cancer (APC) receiving palliative chemotherapy with gemcitabine plus S-1 (GS). This study aimed to validate the application of the GS model in APC patients receiving chemotherapy other than the GS regimen. We retrospectively analyzed 727 APC patients who received first-line palliative chemotherapy other than the GS regimen between 2010 and 2016 at four institutions in Taiwan. The patients were categorized into three prognostic groups based on the GS model for comparisons of survival outcome, best tumor response, and in-group survival differences with monotherapy or combination therapy. The median survival times for the good, intermediate, and poor prognostic groups were 13.4, 8.4, and 4.6 months, respectively. The hazard ratios for the comparisons of intermediate and poor to good prognostic groups were 1.51 (95% confidence interval [CI]), 1.22-1.88, P < .001) and 2.84 (95% CI, 2.34-3.45, P < .001). The best tumor responses with either partial response or stable disease were 57.5%, 40.4%, and 17.2% of patients in the good, intermediate, and poor prognostic groups (P < .001), respectively. For patients...Continue Reading
References
Jun 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·H A BurrisD D Von Hoff
Apr 1, 2008·BMC Cancer·Volker HeinemannChristophe Louvet
Dec 23, 2008·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·E A EisenhauerJ Verweij
Feb 12, 2010·Japanese Journal of Clinical Oncology·De-rong XieYuan-dong Zhang
May 13, 2011·The New England Journal of Medicine·Thierry ConroyUNKNOWN PRODIGE Intergroup
Jun 28, 2011·Oncology·Jun Ho YiJoon Oh Park
Apr 3, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Hideki UenoMasao Tanaka
Oct 18, 2013·The New England Journal of Medicine·Daniel D Von HoffMarkus F Renschler
Mar 20, 2014·British Journal of Cancer·T HamadaK Koike
Jun 29, 2014·BMC Cancer·Gillian K GreshamDerek J Jonker
Sep 11, 2014·The New England Journal of Medicine·David P RyanNabeel Bardeesy
Mar 21, 2015·Journal of Cancer Research and Clinical Oncology·Peng XueLiwei Wang
Jul 1, 2015·International Journal of Clinical Oncology·Tadayuki KouTsutomu Chiba
Feb 3, 2016·Lancet·Terumi KamisawaKyoichi Takaori
Feb 18, 2017·Journal of Cancer Research and Clinical Oncology·Takuji OkusakaUNKNOWN GEST group
Jun 13, 2017·Hepatobiliary & Pancreatic Diseases International : HBPD INT·Shui-Fang JinLi-Ming Jin
Aug 9, 2017·Pancreas·Peng XueMasashi Kanai
Jan 10, 2018·CA: a Cancer Journal for Clinicians·Rebecca L SiegelAhmedin Jemal
Apr 21, 2018·Journal of Cancer·Yi WangLiwei Wang
Jun 2, 2018·Cancer Medicine·Junjie HangHua Jiang
Jul 10, 2018·Gastroenterology Research and Practice·J VentrigliaF De Vita
Jan 13, 2019·Cancers·Ching-Fu ChangWen-Chi Chou
Jan 20, 2019·Journal of Translational Medicine·Ke ZhangHao Chen